A randomized double-blind placebo controlled multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction
Brief Description Of Study
A multi-center study evaluating the effects of ranolazine in subjects with class II/III/IV pulmonary hypertension on stable background therapy and persistent RV dysfunction. Study involves an observational arm and a 26-week treatment arm. At baseline (wk 0), interim (wk 13) and the conclusion of treatment period (wk 26) subjects will be assessed for functional class, 6- MWD, and QOL based on SF-36 tool. Subjects will be assessed with echo and peripheral blood will be obtained for metabolic profiling at baseline and the conclusion of the treatment period. Subjects will have baseline cardiac MRI done per standard of care or will have it done as part of the companion research imaging protocol. Subjects must enroll in companion imaging protocol to qualify for the treatment protocol.